ESMO 2017—my personal highlights

[1]  L. Einhorn,et al.  1297ORandomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC) , 2017 .

[2]  A. Zubel,et al.  994OEquivalent efficacy of a biosimilar rituximab and reference rituximab in previously untreated advanced follicular lymphoma: Extended results of ASSIST-FL, a confirmatory phase III study , 2017 .

[3]  L. Sequist,et al.  LBA49Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC , 2017 .

[4]  Y. Ohe,et al.  LBA2_PROsimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA , 2017 .

[5]  D. Planchard,et al.  LBA1_PRPACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC , 2017 .

[6]  Peter Schmid,et al.  LBA13Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086 , 2017 .

[7]  H. Groen,et al.  Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC) , 2017 .

[8]  E. Devin,et al.  1273OResults of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC) , 2017 .

[9]  M. Piccart,et al.  150O_PRNot all small node negative (pT1abN0) breast cancers are similar: Outcome results from an EORTC 10041/BIG 3-04 (MINDACT) trial substudy , 2017 .

[10]  M. Goetz,et al.  236O_PRMONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer , 2017 .

[11]  M. Shipp,et al.  Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. , 2017, Blood.

[12]  A. LaCasce,et al.  PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. , 2017, Blood.